A small fraction of an ingested dose is metabolized in the liver by the cytochrome P-450 mixed function oxidase enzyme system to form a reactive, potentially toxic, intermediate metabolite which preferentially conjugates with hepatic glutathione to form the nontoxic cysteine and mercapturic acid derivatives which are then excreted by the kidney
A thorough evaluation confirms safety before treatment
April 15, 2026: In the updated 503A document, the FDA announced it is removing BPC-157 (both BPC-157 acetate and BPC-157 free base) from Category 2 and scheduling a PCAC meeting for July 23, 2026
Can be combined with minoxidil or finasteride to enhance results, since it works through entirely different mechanisms
GHK-Cu Estimated refrigerated stability: 4560+ days GHK-Cu differs significantly from most research peptides
AOD-9604 (Advanced Obesity Drug 9604) addresses this challenge through remarkable selectivity